Helixomer utilizes the power of our proprietary RNA origami (RNAO) platform coupled with aptamers to address problems in drug design and development. While aptamers continue to be pursued to overcome the issues in general pharmaceuticals, without RNAO, aptamers have limited benefit to the field.